DDInter71 DDInter1747
An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Aminoglutethimide {u} (Compound) resembles {v} (Compound) Glutethimide
Aminoglutethimide {u} (Compound) binds {v} (Gene) CYP19A1
Aminoglutethimide {u} (Compound) is included by {v} (Pharmacologic Class) Adrenal Steroid Synthesis Inhibitors
Aminoglutethimide {u} (Compound) downregulates {v} (Gene) PSMB8
Aminoglutethimide {u} (Compound) causes {v} (Side Effect) Anaemia
Aminoglutethimide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolbutamide
Aminoglutethimide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glimepiride
Aminoglutethimide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acalabrutinib
Aminoglutethimide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gefitinib
Aminoglutethimide {u} may lead to a major life threatening interaction when taken with {v} Lumateperone
Aminoglutethimide (Compound) resembles Glutethimide (Compound)
Aminoglutethimide (Compound) binds CYP19A1 (Gene)
Aminoglutethimide (Compound) is included by Adrenal Steroid Synthesis Inhibitors (Pharmacologic Class)
Aminoglutethimide (Compound) downregulates PSMB8 (Gene)
Aminoglutethimide (Compound) causes Anaemia (Side Effect)
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Glimepiride
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib
Aminoglutethimide may lead to a major life threatening interaction when taken with Lumateperone